Clinical Study
Effect of Rosiglitazone and Insulin Combination Therapy on Inflammation Parameters and Adipocytokine Levels in Patients with Type 1 DM
Table 3
Comparisons between the groups for inflammatory marker, FFA, and serum adipocytokine levels at baseline and at the final visit (week 16).
| Parameters | Randomization visit | Final visit | Group 1 Insulin + Ros | Group 2 Insulin only | | Group 1 Insulin + Ros | Group 2 Insulin only | |
| ESR (mm/h) | 11.85 ± 11.36 | 10.89 ± 10.39 | 0.969 | 14.44 ± 13.14 | 11.00 ± 8.76 | 0.599 | Fibrinogen (g/L) | 4.00 ± 1.08 | 3.46 ± 0.90 | 0.047 | 3.46 ± 0.90 | 3.11 ± 0.92 | 0.271 | hs-CRP (mg/L) | 2.32 ± 2.64 | 1.41 ± 1.69 | 0.361 | 1.76 ± 1.14 | 1.76 ± 2.31 | 0.443 | FFA (mEq/L) | 0.57 ± 0.43 | 0.49 ± 0.25 | 0.917 | 0.53 ± 0.28 | 0.47 ± 0.26 | 0.518 | Resistin (ng/mL) | 6.96 ± 3.06 | 7.16 ± 2.30 | 0.489 | 4.99 ± 2.64 | 5.57 ± 2.48 | 0.650 | Leptin (ng/mL) | 25.8 ± 17.6 | 16.72 ± 16.1 | 0.130 | 20.1 ± 12.55 | 14.0 ± 13.4 | 0.724 | Adiponectin (µg/mL) | 17.48 ± 10.71 | 11.90 ± 5.23 | 0.760 | 19.81 ± 11.21 | 15.98 ± 9.47 | 0.091 |
|
|
Ros: rosiglitazone; ESR: erythrocyte sedimentation rate; hs-CRP: high-sensitivity C-reactive protein; FFA: free fatty acids.
|